Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
December 2013 Volume 8 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
December 2013 Volume 8 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Lysophosphatidic acid activates β‑catenin/T cell factor signaling, which contributes to the suppression of apoptosis in H19‑7 cells

  • Authors:
    • Yuanjie Sun
    • Nam-Ho Kim
    • Liting Ji
    • Seung-Hyuk Kim
    • Jongho Lee
    • Hae Jin Rhee
  • View Affiliations / Copyright

    Affiliations: Institute of Natural Medicine, College of Medicine, Hallym University, Chuncheon, Gangwon‑do 200‑702, Republic of Korea, Department of Pharmacology, College of Medicine, Hallym University, Chuncheon, Gangwon‑do 200‑702, Republic of Korea, Department of Natural Medicine, College of Medicine, Hallym University, Chuncheon, Gangwon‑do 200‑702, Republic of Korea
  • Pages: 1729-1733
    |
    Published online on: October 18, 2013
       https://doi.org/10.3892/mmr.2013.1743
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Lysophosphatidic acid (LPA) is a lipid growth factor that regulates diverse cell functions, including cell proliferation, survival and apoptosis. LPA has been demonstrated to be involved in the regulation of cortical neurogenesis by increasing the survival of neural precursors. Previously, we reported that LPA stimulated the inactivation of glycogen synthase kinase 3 (GSK3) via the G protein‑coupled LPA1 and LPA2 receptors, by which apoptosis is suppressed in H19‑7 cells [an embryonic hippocampal progenitor cell (HPC) line]. Increasing numbers of studies have demonstrated that certain G protein‑coupled receptors activate β‑catenin/T cell factor (TCF) signaling independently of Wnt, which is involved in cell fate determination, cell proliferation and cell survival. To determine whether LPA activates β‑catenin‑mediated transcriptional activation pathways and whether β‑catenin/TCF signaling is involved in neurogenesis by controlling the survival of neural precursors, β‑catenin/TCF signaling cascades induced by LPA were investigated in the HPCs. Activation of β‑catenin/TCF signaling was determined by the nuclear translocation of β‑catenin and the transcriptional activation of a TCF reporter gene. The activation of β‑catenin/TCF signaling was blocked by pertussis toxin (PTX) and a protein kinase C (PKC) inhibitor. The expression of a constitutively active mutated form of GSK3β activated β‑catenin/TCF signaling to comparable levels to those induced by LPA, and protected against apoptosis in differentiating H19‑7 cells. These results showed that LPA activates β‑catenin/TCF signaling in a PTX- and PKC‑dependent manner, which contributes to LPA‑induced cell survival in the HPCs. Activation of β‑catenin/TCF signaling by LPA may be involved in neurogenesis by controlling the survival of neural precursors.

Introduction

Lysophosphatidic acid (LPA) affects various cell functions, including cell migration, proliferation, differentiation and survival, through a family of cognate G-protein coupled receptors (GPCRs). The binding of LPA to its cognate receptors elicits a range of LPA downstream signaling through at least three different types of G proteins, including Gi/o, Gq/11 and G12/13 (1). LPA is also involved in diverse neurodevelopmental processes, such as neurogenesis, neuritogenesis and neuronal migration. We have previously demonstrated that LPA protected differentiating hippocampal progenitor cells (HPCs) from apoptosis by inhibiting the phosphorylation of glycogen synthase kinase 3 (GSK3) (2), suggesting that LPA may be involved in hippocampal neurogenesis. GSK3 plays a central role in the canonical Wnt/β-catenin signaling pathway, which is shown to be important in neurogenesis by supporting the proliferation of neural stem and precursor cells (3). Previous studies have demonstrated novel aspects of Wnt/β-catenin signaling in neurogenesis. Wnt/β-catenin signaling is involved in neurogenesis by regulating the differentiation of neural precursors (4–7). Moreover, studies have revealed that β-catenin signaling promotes the survival of neuronal cells, including precursor cells (8–12). This has led to the hypothesis that β-catenin signaling may regulate neurogenesis by modulating the survival of neuronal progenitor cells (NPCs). LPA is also involved in the regulation of cortical neurogenesis by controlling the survival of NPCs in ex vivo cortical culture systems, although the molecular mechanism for this is not fully understood (13). Increasing data demonstrate that the activation of G proteins alone, or the activation of GPCRs by agonists such as lipid metabolites and growth factors, may induce the stabilization of β-catenin and the subsequent β-catenin/T cell factor (TCF) transcriptional activation that is independent of Wnt (14,15).

In the present study, it was investigated whether LPA induced β-catenin/TCF transcriptional activation and whether β-catenin/TCF signaling by LPA was involved in the control of NPC survival. It was demonstrated that LPA activated the β-catenin/TCF signaling predominantly in Gi/o- and protein kinase C (PKC)-dependent pathways, and that the β-catenin/TCF signaling induced by LPA was involved in the suppression of apoptosis in differentiating H19-7 cells. Therefore, the activation of the β-catenin/TCF signaling pathway by LPA may function in neurogenesis by controlling the survival of neural precursors.

Materials and methods

Materials

H19-7 cells were generously provided by Dr. Kwang C. Chung (Yonsei University, Seoul, Republic of Korea). LPA (1-oleoyl-2-hydroxy-sn-glycero-3-phosphate), 5-bromodeoxyuridine (BrdU), fatty acid-free bovine serum albumin and pertussis toxin (PTX) were purchased from Sigma (St. Louis, MO, USA). Wortmannin and GF109203 were purchased from Tocris Bioscience (Bristol, UK). TOP Flash and FOP Flash luciferase reporters were purchased from Upstate Biotechnology (Lake Placid, NY, USA). Alexa Fluor 568-conjugated Annexin V was purchased from Invitrogen Life Technologies (Carlsbad, CA, USA). Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS) and G418 were obtained from Invitrogen Life Technologies. All other reagents were of analytical grade or the highest purity available.

Cell culture

H19-7 cells, conditionally immortalized, embryonic (day 17) rat hippocampal cells with a temperature-sensitive SV40 large T antigen (16), were maintained at 33ºC (the permissive temperature at which SV40 large T is functional) in DMEM supplemented with 10% FBS, 0.2 mg/ml G418, 50 U/ml penicillin and 50 mg/ml streptomycin. For differentiation, H19-7 cells were shifted to 39ºC to eliminate the expression of the functional large T antigen, then incubated for 24 h in DMEM supplemented with N2 (N2 medium), and treated with LPA. The differentiation of H19-7 cells into neuronal cells was confirmed by the expression of neuronal markers, such as neurofilament-M and neuron specific enolase, and cell morphology as previously described (17). To determine effect of pharmacological inhibitors on the TCF transcriptional activation and inhibitory phosphorylation of GSK3β induced by LPA, the H19-7 cells were pretreated with the inhibitor for 1 h before LPA treatment.

Measurement of apoptosis by Annexin V staining

Apoptosis was measured by staining with Annexin V conjugated to Alexa Fluor 568 (Life Technologies, Grand Island, NY, USA) as previously described (2). H19-7 cells were collected, washed with phosphate-buffered saline (PBS) and resuspended in 100 μl binding buffer [10 mM HEPES (pH 7.4), 140 mM NaCl and 2.5 mM CaCl2]. The cells were then incubated with 5 μl Annexin V-Alexa Fluor 568 for 15 min at room temperature in the dark, followed by the addition of 400 μl binding buffer. The cells were analyzed by flow cytometry using a Guava EasyCyte (GE Healthcare, Piscataway, NJ, USA).

Western blot analysis

H19-7 cells were collected by brief centrifugation at 500 × g and resuspended in lysis buffer [10 mM HEPES (pH 7.5), 10 mM KCl, 1 mM EGTA, 1 mM EDTA, 1% Nonidet P-40, 1 mM Na3VO4, 5 mM NaF and protease inhibitor cocktail]. Following incubation on ice for 10 min, cell lysates were centrifuged at 4,000 × g for 1 min. Supernatants containing cytoplasm were collected and the remaining nuclear pellet was resuspended in lysis buffer containing 0.1% sodium dodecyl sulphate (SDS). The protein concentrations within each lysate were determined by the Bradford assay (Bio-Rad, Richmond, CA, USA). The fractionated extracts were mixed with SDS sample buffer and equal quantities of the samples were loaded and separated by SDS-polyacrylamide gel electrophoresis (8 or 10% reducing gels), transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA) and blocked with 5% non-fat milk. The membranes were incubated in primary antibody overnight at 4ºC. Subsequent to this, the membranes were washed in TBST [10 mM Tris, 140 mM NaCl and 0.1% Tween-20 (pH 7.6)], incubated with the appropriate secondary antibody and washed again in TBST. Bands were visualized by enhanced chemiluminescence and exposed to X-ray film.

Immunocytochemistry

Differentiating H19-7 cells cultivated on chamber slides (Nalgene, Rochester, NY, USA) were treated with LPA. The cells were fixed and permeabilized as described in a previous study (2), processed for immunocytochemistry with mouse anti-β-tublin III (Sigma) or rabbit anti-β-catenin (Abcam, Cambridge, MA, USA), and subsequently processed with Alexa Fluor 568- or Alexa Fluor 488-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA). The stained cells were observed using a fluorescence microscope (Axio Scope A1; Zeiss, Oberkochen, Germany) with a digital camera attachment.

Luciferase reporter gene assay

H19-7 cells were transiently transfected with a luciferase reporter and Renilla luciferase (pRL-TK; Promega Corporation, Madisson, WI, USA) with the indicated plasmids, using FuGene HD (Roche Molecular Biochemicals, Mannheim Germany). The luciferase reporter constructs TOP Flash and FOP Flash (Upstate Biotechnology) were used to determine the TCF/lymphoid enhancing factor (LEF) transcription activity. Following transfection for 6 h, the cells were cultivated in N2 medium for 18 h and to induce differentiation as described previously. The cells were treated with LPA or vehicle for 4 h and collected. The cell extracts were prepared by rinsing each plate twice with PBS and lysing the cells in 150 μl Reporter Assay Lysis buffer (Promega Corporation). The cell lysates were collected, normalized for protein content and assayed using a dual luciferase assay system (Promega Corporation). They were analyzed for firefly luciferase (TOP Flash or FOP Flash) activity, and the reactions were quenched and immediately reanalyzed for Renilla luciferase activity using an Autolumat Luminometer (Berthhold Technologies, Oak Ridge, TN, USA).

Statistical analysis

Results are presented as the mean ± SEM. Statistical significance was analyzed by one-way analysis of variance followed by a Dunnett’s multiple test or a paired t-test using Prism (GradPad Software, La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

LPA induces activation of β-catenin/TCF signaling in H19-7 cells

In a previous study, it was demonstrated that LPA stimulated the inactivation of GSK-3 in H19-7 cells through LPA1 and LPA2(2). As β-catenin is a substrate for GSK3 and is degraded following phosphorylation by GSK3, and as LPA activates G proteins, such as Gq, Gi/o and G12/13 (via coupling to LPA1 and LPA2), LPA may activate β-catenin/TCF signaling in H19-7 cells. To determine whether LPA activated β-catenin/TCF signaling, cytoplasmic and nuclear levels of β-catenin in the H19-7 cells treated with LPA were investigated by immunocytochemistry and western blot analysis. An increase in the level and the nuclear translocation of β-catenin was detected by immunocytochemistry in the H19-7 cells (Fig. 1A). In addition, an increase in the cytoplasmic levels of β-catenin and the subsequent increase in the levels of nuclear β-catenin was demonstrated by western blot analysis (Fig. 1B). An increase in the level of nuclear β-catenin was also detected within 30 min (data not shown). To determine whether LPA activated β-catenin-mediated transcriptional activation, the TCF reporter activity was analyzed in differentiating H19-7 cells transfected with TCF luciferase reporter. TCF with LPA reporter activity was ~2-fold that without LPA, and was similar to that induced by transfection with a plasmid encoding β-catenin truncated N-terminal 90 amino acids (b-CatΔ90) acting as a constitutively active mutant of β-catenin (CA-β-catenin) (Fig. 1C).

Figure 1

Lysophosphatidic acid (LPA) activated β-catenin/T cell factor (TCF) signaling in differentiating H19-7 cells. H19-7 cells were induced to differentiate and were treated with 5 μM LPA or vehicle. (A) The cells were fixed, immunostained with anti-β-catenin or anti-tublin III and detected with secondary antibody conjugated with Alexa Fluor 568 and Alexa Fluor 488, respectively. Scale bar, 10 μm. (B) The cells were lysed and fractionated and the levels of β-catenin in the cytoplasm and nucleus were determined by western blot analysis. Representatives of two independent experiments are shown. (C) H19-7 cells were transfected with TOP Flash or POP Flash and pRL-TK, along with additional plasmid encoding CA-β-catenin or empty vector before inducing differentiation. The cells were treated with LPA or vehicle, and TCF reporter transcriptional activity was demonstrated by determining the ratio of TOP-Flash to POP-Flash, as described in the Materials and methods. Each point represents the mean ± SEM of triplicate samples. Data are representative of three independent experiments.

LPA activates β-catenin/TCF signaling in a PTX- and PKC-dependent manner

Our previous study demonstrated that LPA induced cell survival in a PTX-dependent manner by the post-translational upregulation of Mcl-1 through the inhibitory phosphorylation of GSK3 in differentiating H19-7 cells. The inhibitory phosphorylation of GSK3 is mediated predominantly by PKC and partly by mitogen activated protein kinases, PKA and phosphatidylinositol 3-kinase (PI3K) in the H19-7 cells (2). To determine the mechanism by which LPA stimulates β-catenin/TCF signaling, the effect of pharmacological inhibitors of PKC, PI3K and Gi/o on the LPA-induced activation of the TCF reporter activity and on the inhibitory phosphorylation of GSK3β at Ser9 by LPA was analyzed. GF109203 (a PKC inhibitor) and PTX (a Gi/o specific inhibitor) significantly decreased the LPA-induced activation of TCF reporter activity, whereas wortmannin (a PI3K inhibitor) did not significantly decrease this activation. By contrast, the LPA-induced inhibitory phosphorylation of GSK3β was marginally decreased by PTX and not by wortmannin, while GF109203 completely inhibited the phosphorylation (Fig. 2). The observation that PTX significantly inhibited the LPA-induced β-catenin/TCF signaling, with a marginal decrease in the inhibitory phosphorylation of GSK3β, suggested that LPA may stimulate β-catenin/TCF transactivation via signaling pathways that are independent of the direct inhibition of GSK3.

Figure 2

Effect of pharmacological inhibitors on the T cell factor (TCF) transcriptional activity and inhibitory phosphorylation of glycogen synthase kinase (GSK)3β. (A) H19-7 cells were transiently transfected with TOP Flash or FOP Flash, and differentiation was induced. The differentiating cells were pretreated with 10 μM GF109203, 2 μM wortmannin and 100 ng/ml pertussis toxin (PTX) for 1 h, and treated with LPA (5 μM) or vehicle for 4 h. The cells were collected and TCF reporter activity was determined. Results are presented as the mean of triplicate samples from three independent experiments. The value in the absence of inhibitor (control) versus value in the presence of inhibitor are significantly different (n=9, **P<0.001). (B) Differentiating H19-7 cells were treated with 10 μM GF109203, 2 μM wortmannin and 100 ng/ml PTX for 1 h, and treated with LPA (5 μM) or vehicle for 4 h. Inhibitory phosphorylation of GSK3β was detected using anti-GSK-3βSer9 (Cell Signaling Technology Inc., Berverly, MA, USA) by western blot analysis. Data are representative of three independent experiments.

Activation of β-catenin/TCF transcription by LPA suppresses the apoptosis of H19-7 cells

LPA induced cell survival in a dose-responsive manner in the differentiating H19-7 cells; however, the H19-7 cells treated with LPA were not stained with BrdU, suggesting that LPA induced cell survival by protecting H19-7 cells from cell death, not by inducing cell proliferation (data not shown). To determine whether LPA-mediated β-catenin/TCF signaling was involved in protecting H19-7 cells from cell death, the cells were transfected with a plasmid expressing either CA-β-catenin or empty vector and a plasmid expressing GFP. Transfected cells differentiated and apoptosis was detected by flow cytometry as described in the Materials and methods. Apoptosis was significantly suppressed in the H19-7 cells expressing CA-β-catenin compared with that of the control cells (Fig. 3).

Figure 3

β-catenin/T cell factor signaling by lysophosphatidic acid (LPA) suppresses apoptosis in differentiating H19-7 cells. (A) Cells were transfected with pCatDt90, a plasmid expressing CA-β-catenin, or empty vector (control) with phosphorylated enhanced green fluorescent protein (pEGFP). Differentiation was induced and cells were treated with LPA at 39ºC for 4 h. The cells were harvested, stained with Annexin V conjugated with Alexa Fluor 568 and analyzed by flow cytometry. The intensity of the red fluorescence of Annexin V-Alexa Fluor 568 is shown on the y-axis, the intensity of GFP is shown on the x-axis and the populations of apoptotic cells among cells expressing b-CatΔ90 or control cells in the quadrant are shown. Data are representative of two independent experiments. (B) Quantitation of apoptotic cells among the transfected cells with pCatDt90 or empty vector (pcDNA3). Apoptosis was significantly reduced in H19-7 cells transfected with pCatDt90 compared with the control. Results are the mean of triplicate samples from two independent experiments (n=6; **P<0.01, vs. control).

Discussion

Activation of the cognate GPCRs by lipid metabolites, growth factors or a P2Y receptor agonist was shown to activate β-catenin/TCF signaling, although the mechanism of action is unclear. The GPCR-mediated β-catenin/TCF transcriptional activation (except for the P2Y receptor-mediated TCF activation) was demonstrated to be implicated in oncogenicity, including cell proliferation and epithelial-mesenchymal transition in cancer cells, but not in normal physiological processes (18–23). In the present study, it was demonstrated that LPA activated β-catenin/TCF signaling predominantly via the Gi/o- and PKC-dependent pathways in differentiating HPCs, and that the β-catenin/TCF signaling induced by LPA was involved in suppressing apoptosis in the HPCs. Activation of β-catenin/TCF signaling was determined by an increase in the nuclear levels of β-catenin and the stimulation of TCF reporter activity (Fig. 1). The observation that β-catenin/TCF transactivation induced the expression of Mcl-1, an anti-apoptotic Bcl2 family member (24), was consistent with a previous study demonstrating that LPA-induced cell survival was mediated by post-translational and transcriptional upregulation of Mcl-1 (2). Whether the direct inhibition of GSK3β is involved in β-catenin stabilization and subsequent β-catenin/TCF transactivation remains controversial. LPA was previously shown to induce the inhibitory phosphorylation of GSK3β by PKC, mitogen-activated protein kinase and protein kinase A, but not PI3K, in H19-7 cells (2). Therefore, in the present study, it was investigated whether inhibitory phosphorylation of GSK3β by upstream kinases was involved in the β-catenin/TCF transactivation. LPA-induced activation of β-catenin/TCF signaling was significantly inhibited by PTX, although PTX marginally decreased the inhibitory phosphorylation of GSK3β. Moreover, the PKC inhibitor decreased the β-catenin/TCF signaling less potently than that by PTX, although the PKC inhibitor completely abolished the inhibitory phosphorylation of GSK3β. Thus, these results suggested that LPA may activate β-catenin/TCF transactivation via signaling pathways that are independent of the direct inhibition of GSK3. However, β-catenin/TCF transactivation may have occurred through direct inhibition of GSK3β, as the PKC inhibitor significantly decreased the activation of β-catenin/TCF signaling and the inhibitory phosphorylation of GSK3β. Previous studies have suggested that GSK3β only modifies β-catenin when GSK3 forms the Axin/APC/β-catenin destructive complex (25,26), and that only a small pool of GSK3β exists in the Axin scaffolding complex within which GSK3β is not readily accessible to upstream kinases (27). Thus, GPCR-mediated activation of β-catenin/TCF signaling may occur without direct inhibitory phosphorylation of GSK3β in the Axin scaffolding complex, although upstream kinases are involved in this signaling pathway and inhibitory phosphorylation of GSK3β in the other pool is increased. Alternatively to the phosphorylation of GSK3 within the Axin complex, the upstream kinases may activate β-catenin/TCF signaling by acting on other targets involved in the activation of β-catenin/TCF signaling, such as 14-3-3-mediated nuclear efflux of β-catenin by Akt or PKC and KSRP-mediated stabilization of β-catenin mRNA by PI3K/Akt (28–30). Thus, PKC may activate β-catenin/TCF signaling without inhibitory phosphorylation of GSK3β in the Axin complex, although the total inhibitory phosphorylation of GSK3β is increased.

Expression of CA-β-catenin suppressed apoptosis in differentiating H19-7 cells, suggesting that the activation of the TCF reporter activity by LPA was involved in cell survival of HPCs. Apoptosis of the H19-7 cells was suppressed by 6% following expression of CA-β-catenin (Fig. 3). Suppressive effects of β-catenin/TCF activation on the survival of the H19-7 cells were marginal, but may be physiologically relevant, as small changes in the survival of progenitor pools may produce a marked effect on neurodevelopment. It was suggested that only a 3.5% increase in survival and a 2.5% increase in terminal mitosis of progenitor cells induced an ~30% increase in the thickness of the cerebral cortical wall (13). In concordance with the present results, previous studies demonstrated that β-catenin/TCF signaling was involved in the survival of neural precursors, although the molecular mechanisms remain unknown (31–33). In conclusion, the results suggested that LPA may regulate β-catenin/TCF signaling in NPCs, as LPA is involved in neurogenesis by controlling the survival of neural precursors.

Acknowledgements

This study was supported by the National Research Foundation of Korea Grant funded by the Korean Government (grant no. 2010-0005848), and by the Priority Research Centers Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science and Technology (grant no. NRF-2009-0094071).

References

1 

Anliker B and Chun J: Lysophospholipid G protein-coupled receptors. J Biol Chem. 279:20555–20558. 2004. View Article : Google Scholar : PubMed/NCBI

2 

Sun Y, Nam JS, Han DH, et al: Lysophosphatidic acid induces upregulation of Mcl-1 and protects apoptosis in a PTX-dependent manner in H19-7 cells. Cell Signal. 22:484–494. 2010. View Article : Google Scholar : PubMed/NCBI

3 

Zhang L, Yang X, Yang S and Zhang J: The Wnt/β-catenin signaling pathway in the adult neurogenesis. Eur J Neurosci. 33:1–8. 2011.

4 

Ille F, Atanasoski S, Falk S, et al: Wnt/BMP signal integration regulates the balance between proliferation and differentiation of neuroepithelial cells in the dorsal spinal cord. Dev Biol. 304:394–408. 2007. View Article : Google Scholar : PubMed/NCBI

5 

Zhang J, Woodhead GJ, Swaminathan SK, et al: Cortical neural precursors inhibit their own differentiation via N-cadherin maintenance of beta-catenin signaling. Dev Cell. 18:472–479. 2010. View Article : Google Scholar : PubMed/NCBI

6 

Wang X, Kopinke D, Lin J, et al: Wnt signaling regulates postembryonic hypothalamic progenitor differentiation. Dev Cell. 23:624–636. 2012. View Article : Google Scholar : PubMed/NCBI

7 

Tang M, Villaescusa JC, Luo SX, et al: Interactions of Wnt/beta-catenin signaling and sonic hedgehog regulate the neurogenesis of ventral midbrain dopamine neurons. J Neurosci. 30:9280–9291. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Pöschl J, Grammel D, Dorostkar MM, Kretzschmar HA and Schüller U: Constitutive activation of β-catenin in neural progenitors results in disrupted proliferation and migration of neurons within the central nervous system. Dev Biol. 374:319–332. 2013.

9 

Zhao S, Fu J, Liu X, Wang T, Zhang J and Zhao Y: Activation of Akt/GSK-3beta/beta-catenin signaling pathway is involved in survival of neurons after traumatic brain injury in rats. Neurol Res. 34:400–407. 2012. View Article : Google Scholar : PubMed/NCBI

10 

Pérez-Álvarez MJ, del Maza MC, Anton M, Ordoñez L and Wandosell F: Post-ischemic estradiol treatment reduced glial response and triggers distinct cortical and hippocampal signaling in a rat model of cerebral ischemia. J Neuroinflammation. 9:1572012.

11 

Mavila N, James D, Utley S, et al: Fibroblast growth factor receptor-mediated activation of AKT-β-catenin-CBP pathway regulates survival and proliferation of murine hepatoblasts and hepatic tumor initiating stem cells. PloS One. 7:e504012012.

12 

Lei ZN, Liu F, Zhang LM, Huang YL and Sun FY: Bcl-2 increases stroke-induced striatal neurogenesis in adult brains by inhibiting BMP-4 function via activation of β-catenin signaling. Neurochem Int. 61:34–42. 2012.PubMed/NCBI

13 

Kingsbury Ma, Rehen SK, Contos JJ, Higgins CM and Chun J: Non-proliferative effects of lysophosphatidic acid enhance cortical growth and folding. Nat Neurosci. 6:1292–1299. 2003. View Article : Google Scholar : PubMed/NCBI

14 

Valenta T, Hausmann G and Basler K: The many faces and functions of β-catenin. EMBO J. 31:2714–2736. 2012.

15 

Jin T, George Fantus I and Sun J: Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of beta-catenin. Cell Signal. 20:1697–1704. 2008. View Article : Google Scholar : PubMed/NCBI

16 

Eves EM, Boise LH, Thompson CB, Wagner AJ, Hay N and Rosner MR: Apoptosis induced by differentiation or serum deprivation in an immortalized central nervous system neuronal cell line. J Neurochem. 67:1908–1920. 1996. View Article : Google Scholar : PubMed/NCBI

17 

Rhee HJ, Nam JS, Sun Y, et al: Lysophosphatidic acid stimulates cAMP accumulation and cAMP response element-binding protein phosphorylation in immortalized hippocampal progenitor cells. Neuroreport. 17:523–526. 2006. View Article : Google Scholar : PubMed/NCBI

18 

Yang M, Zhong WW, Srivastava N, et al: G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the β-catenin pathway. Proc Natl Acad Sci USA. 102:6027–6032. 2005.PubMed/NCBI

19 

Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoël MJ, et al: Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene. 20:252–259. 2001. View Article : Google Scholar : PubMed/NCBI

20 

Castellone MD, Teramoto H, Williams BO, Druey KM and Gutkind JS: Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science. 310:1504–1510. 2005. View Article : Google Scholar : PubMed/NCBI

21 

Verras M and Sun Z: Beta-catenin is involved in insulin-like growth factor 1-mediated transactivation of the androgen receptor. Mol Endocrinol. 19:391–398. 2005. View Article : Google Scholar : PubMed/NCBI

22 

Ortega F, Pérez-Sen R and Miras-Portugal MT: Gi-coupled P2Y-ADP receptor mediates GSK-3 phosphorylation and beta-catenin nuclear translocation in granule neurons. J Neurochem. 104:62–73. 2008.PubMed/NCBI

23 

Yi F, Sun J, Lim GE, Fantus IG, Brubaker PL and Jin T: Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology. 149:2341–2351. 2008. View Article : Google Scholar : PubMed/NCBI

24 

Iqbal S, Zhang S, Driss A, et al: PDGF upregulates Mcl-1 through activation of β-catenin and HIF-1α-dependent signaling in human prostate cancer cells. PloS One. 7:e307642012.PubMed/NCBI

25 

Hur EM and Zhou FQ: GSK3 signalling in neural development. Nat Rev Neurosci. 11:539–551. 2010. View Article : Google Scholar : PubMed/NCBI

26 

Wu D and Pan W: GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem Sci. 35:161–168. 2010. View Article : Google Scholar : PubMed/NCBI

27 

Ng SS, Mahmoudi T, Danenberg E, et al: Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade. J Biol Chem. 284:35308–35313. 2009. View Article : Google Scholar : PubMed/NCBI

28 

Gherzi R, Trabucchi M, Ponassi M, et al: The RNA-binding protein KSRP promotes decay of beta-catenin mRNA and is inactivated by PI3K-AKT signaling. PLoS Biol. 5:e52006. View Article : Google Scholar : PubMed/NCBI

29 

Takemaru K, Fischer V and Li FQ: Fine-tuning of nuclear-catenin by Chibby and 14-3-3. Cell Cycle. 8:210–213. 2009. View Article : Google Scholar : PubMed/NCBI

30 

Luna-Ulloa LB, Hernández-Maqueda JG, Santoyo-Ramos P, Castañeda-Patlán MC and Robles-Flores M: Protein kinase C ζ is a positive modulator of canonical Wnt signaling pathway in tumoral colon cell lines. Carcinogenesis. 32:1615–1624. 2011.

31 

Paek H, Hwang JY, Zukin RS and Hébert JM: β-Catenin-dependent FGF signaling sustains cell survival in the anterior embryonic head by countering Smad4. Dev Cell. 20:689–699. 2011.

32 

Holowacz T, Huelsken J, Dufort D and van der Kooy D: Neural stem cells are increased after loss of β-catenin, but neural progenitors undergo cell death. Eur J Neurosci. 33:1366–1375. 2011.

33 

Chen BY, Wang X, Wang ZY, Wang YZ, Chen LW and Luo ZJ: Brain-derived neurotrophic factor stimulates proliferation and differentiation of neural stem cells, possibly by triggering the Wnt/β-catenin signaling pathway. J Neurosci Res. 91:30–41. 2013.PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Sun Y, Kim N, Ji L, Kim S, Lee J and Rhee HJ: Lysophosphatidic acid activates β‑catenin/T cell factor signaling, which contributes to the suppression of apoptosis in H19‑7 cells. Mol Med Rep 8: 1729-1733, 2013.
APA
Sun, Y., Kim, N., Ji, L., Kim, S., Lee, J., & Rhee, H.J. (2013). Lysophosphatidic acid activates β‑catenin/T cell factor signaling, which contributes to the suppression of apoptosis in H19‑7 cells. Molecular Medicine Reports, 8, 1729-1733. https://doi.org/10.3892/mmr.2013.1743
MLA
Sun, Y., Kim, N., Ji, L., Kim, S., Lee, J., Rhee, H. J."Lysophosphatidic acid activates β‑catenin/T cell factor signaling, which contributes to the suppression of apoptosis in H19‑7 cells". Molecular Medicine Reports 8.6 (2013): 1729-1733.
Chicago
Sun, Y., Kim, N., Ji, L., Kim, S., Lee, J., Rhee, H. J."Lysophosphatidic acid activates β‑catenin/T cell factor signaling, which contributes to the suppression of apoptosis in H19‑7 cells". Molecular Medicine Reports 8, no. 6 (2013): 1729-1733. https://doi.org/10.3892/mmr.2013.1743
Copy and paste a formatted citation
x
Spandidos Publications style
Sun Y, Kim N, Ji L, Kim S, Lee J and Rhee HJ: Lysophosphatidic acid activates β‑catenin/T cell factor signaling, which contributes to the suppression of apoptosis in H19‑7 cells. Mol Med Rep 8: 1729-1733, 2013.
APA
Sun, Y., Kim, N., Ji, L., Kim, S., Lee, J., & Rhee, H.J. (2013). Lysophosphatidic acid activates β‑catenin/T cell factor signaling, which contributes to the suppression of apoptosis in H19‑7 cells. Molecular Medicine Reports, 8, 1729-1733. https://doi.org/10.3892/mmr.2013.1743
MLA
Sun, Y., Kim, N., Ji, L., Kim, S., Lee, J., Rhee, H. J."Lysophosphatidic acid activates β‑catenin/T cell factor signaling, which contributes to the suppression of apoptosis in H19‑7 cells". Molecular Medicine Reports 8.6 (2013): 1729-1733.
Chicago
Sun, Y., Kim, N., Ji, L., Kim, S., Lee, J., Rhee, H. J."Lysophosphatidic acid activates β‑catenin/T cell factor signaling, which contributes to the suppression of apoptosis in H19‑7 cells". Molecular Medicine Reports 8, no. 6 (2013): 1729-1733. https://doi.org/10.3892/mmr.2013.1743
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team